[Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study].

R Ferrandis,B Escontrela,C Ferrando,M Hernández,J Herrera,F Hidalgo,J Librero,J V Llau,A Martínez,A Pajares,B Tapia,E Arruti,E Bassas,A Blasi,A Calvo

Revista espanola de anestesiologia y reanimacion（2023）

引用 1|浏览5

暂无评分

摘要

We found no benefit or harm with the administration of therapeutic or prophylactic LMWH dose in COVID19 critically ill patients. With a similar rate of hemorrhagic or thrombotic events, the LMWH dose had no influence on mortality. More studies are needed to determine the optimal thromboprophylaxis protocol for critically ill patients.

查看译文

关键词

COVID-19,Critically ill patients,Haemorrhagic complications,Low-molecular-weight heparin,Thromboprohylaxis,Thrombotic complications

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要